Fisher & Paykel Healthcare Corporation Limited — Cyborg Score 7/10

Solid
Medical Devices - Respiratory Care & Home Healthcare Equipment

Strategic Profile

The company invested $226.9 million in R&D during 2025 and expanded rollout of key products like F&P Airvo™ 3 and F&P 950™ System in the US market. Gross margin for FY 2026 is expected to improve by 50 basis points despite a 75 bps tariff impact, with operating expense growth remaining below long-term revenue growth aspirations.

Cyborg Score Rationale

The company demonstrated substantial 10% revenue growth driven by strong home care performance and product innovations, though it faced a 56% decline in net profit after tax. Tariff headwinds offset by margin improvements and strong innovation pipeline position FPH as a solid mid-tier healthcare equipment player navigating near-term profitability challenges.

Top Insights

  • Approximately 45% of manufacturing volume comes from Mexico and 55% from New Zealand, with 43% of FY2025 revenue from the US market
  • FY 2026 gross margin expected to improve 50 basis points despite 75 basis point tariff impact, showing successful cost mitigation efforts
  • Recent product launches include F&P Airvo 3 expansion, Optiflow anesthesia devices, and new OSA masks (Nova Micro and Nova Nasal)
  • Trading at a high P/S ratio of 12.3x versus peer average of 3.7x, suggesting premium valuation dependent on growth execution

Named Competitors

  • ResMed — Cloud-connected medical devices for respiratory care and sleep apnea
  • Philips Respiratory Care — Ventilation and acute care respiratory systems
  • Puritan Bennett — Hospital ventilation and anesthesia systems
  • GE Healthcare Respiratory — Hospital-based ventilation and monitoring systems

Recent Developments

  • (February 2026) Stock price declined 7.08% to $36.61 NZD amid market correction
  • (May 2025) Record full-year revenue announced with 2% dividend increase to 42.5 cents per share
  • (February 2025) US tariff announcement triggers 75 basis point cost impact; company maintains FY2025 profit guidance

Open the full interactive Fisher & Paykel Healthcare Corporation Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →